Correction to “Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia”

IF 14.6 2区医学 Q1 HEMATOLOGY

HemaSphere Pub Date : 2025-09-23 DOI:10.1002/hem3.70219

引用次数: 0

Abstract

Frustaci AM, Zappaterra A, Galitzia A, et al. Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia. HemaSphere. 2025;9(2):e70094. doi:10.1002/hem3.70094

In the Funding section, the funder was incorrectly listed. The funder statement now reads: “Open access publishing facilitated by Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, as part of the Wiley – SBBL agreement.”

The original article has been updated. We apologize for this error.

Abstract Image

查看原文本刊更多论文

更正“共价BTKi失败后的抢救治疗：Waldenstrom巨球蛋白血症临床实践中未满足的需求”。

[这更正了文章DOI: 10.1002/hem3.70094.]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HemaSphere Medicine-Hematology

CiteScore

6.10

自引率

4.50%

发文量

2776

审稿时长

7 weeks

期刊介绍： HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.